- Home
- ADAP vs LSTA Comparison
ADAP vs LSTA Comparison
Compare ADAP & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- LSTA
- Stock Information
- Founded
- ADAP 2008
- LSTA 1980
- Country
- ADAP United Kingdom
- LSTA United States
- Employees
- ADAP N/A
- LSTA N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- LSTA Misc Health and Biotechnology Services
- Sector
- ADAP Health Care
- LSTA Health Care
- Exchange
- ADAP Nasdaq
- LSTA Nasdaq
- Market Cap
- ADAP 21.3M
- LSTA 20.9M
- IPO Year
- ADAP 2015
- LSTA N/A
- Fundamental
- Price
- ADAP $0.14
- LSTA $2.43
- Analyst Decision
- ADAP Hold
- LSTA Strong Buy
- Analyst Count
- ADAP 6
- LSTA 2
- Target Price
- ADAP $1.02
- LSTA $23.50
- AVG Volume (30 Days)
- ADAP 139.0M
- LSTA 22.8K
- Earning Date
- ADAP 11-12-2025
- LSTA 11-11-2025
- Dividend Yield
- ADAP N/A
- LSTA N/A
- EPS Growth
- ADAP N/A
- LSTA N/A
- EPS
- ADAP N/A
- LSTA N/A
- Revenue
- ADAP $65,084,999.00
- LSTA $1,070,000.00
- Revenue This Year
- ADAP N/A
- LSTA N/A
- Revenue Next Year
- ADAP $24.70
- LSTA N/A
- P/E Ratio
- ADAP N/A
- LSTA N/A
- Revenue Growth
- ADAP N/A
- LSTA N/A
- 52 Week Low
- ADAP $0.04
- LSTA $1.87
- 52 Week High
- ADAP $0.96
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- ADAP 56.57
- LSTA 49.40
- Support Level
- ADAP $0.12
- LSTA $2.36
- Resistance Level
- ADAP $0.16
- LSTA $2.62
- Average True Range (ATR)
- ADAP 0.03
- LSTA 0.18
- MACD
- ADAP 0.00
- LSTA 0.02
- Stochastic Oscillator
- ADAP 39.87
- LSTA 54.72
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.